Last reviewed · How we verify
Paroxetine+Bupropion
This combination inhibits serotonin reuptake (paroxetine) and norepinephrine/dopamine reuptake (bupropion) to increase monoamine neurotransmitter levels in the brain.
This combination inhibits serotonin reuptake (paroxetine) and norepinephrine/dopamine reuptake (bupropion) to increase monoamine neurotransmitter levels in the brain. Used for Major depressive disorder, Depression with anhedonia or fatigue.
At a glance
| Generic name | Paroxetine+Bupropion |
|---|---|
| Also known as | Seroxat, wellbutrin |
| Sponsor | Ministry of Health & Welfare, Korea |
| Drug class | SSRI + NDRI combination antidepressant |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake at the presynaptic neuron, increasing synaptic serotonin availability. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that blocks reuptake of norepinephrine and dopamine, complementing the serotonergic effect. Together, they provide broader monoaminergic coverage for treating depression and related mood disorders.
Approved indications
- Major depressive disorder
- Depression with anhedonia or fatigue
Common side effects
- Nausea
- Insomnia
- Headache
- Dry mouth
- Tremor
- Sexual dysfunction
- Seizure risk (bupropion component)
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities (PHASE4)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk (PHASE2)
- eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine+Bupropion CI brief — competitive landscape report
- Paroxetine+Bupropion updates RSS · CI watch RSS
- Ministry of Health & Welfare, Korea portfolio CI